| abstract |
The compounds of formula (I) provide pharmacological agents that bind to the Peroxysome Proliferator-Activated Receptor (PPAR). Thus, the compounds of the present invention are useful for the treatment of conditions mediated by PPAR receptor activity in mammals. These conditions include dyslipidemia, hyperlipidemia, hypercholesterolemia, arteriosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular disease, cardiovascular disease, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders , Respiratory disease, eye disorders, irritable bowel disease (IBD), ulcerative colitis, Crohn's disease, and conditions associated with impaired glucose tolerance, hyperglycemia and insulin resistance (eg type 1 and type 2 diabetes), and syndrome X.n n n <Formula I> |